Table 1.
List of AAV-vectored immunotherapeutic strategies.
| Pathogen | AAV serotype | Animal | Injection route | Therapeutic mode | References |
|---|---|---|---|---|---|
| HIV | Mouse | IM | bNAb | Lewis 2002 (91) | |
| AAV2/8 | Mouse | IM | bNAb | Balazs 2011 (92) | |
| AAV1 | Rh.M. | IM | bNAb-derived immunoadhesins | Johnson 2009 (93) | |
| AAV1 | Rh.M. | IM | bNAb | Fuchs 2015 (70); Martinez-Navio 2019 (71) | |
| AAV8 | Rh.M | IM | bNAb | Welles 2018 (88); Saunders 2015 (94) | |
| AAV1 | Human | IM | bNAb | Priddy 2019 (89) | |
| AAV1 | Rh.M. | IM | eCD4-Ig | Gardner 2015 (95); 2019 (96) | |
| Flu | AAV2/8 | Mouse | IM | bNAb | Balazs 2013 (97) |
| AAV9 | Mouse, Ferret | IN | bNAb | Limberis 2013a (98), 2013b (99); Adam 2014 (100) | |
| AAV9 | Mouse | IN | Multi-domain Ab | Laursen 2018 (101) | |
| AAV8 | Mouse | IM | Nanobody | Del Rosario 2020 (102) | |
| AAV8 | Mouse | IV | 2CARD-MAVS | Nistal-Villán 2015 (103) | |
| AAV9 | Mouse | IN | HA/antigen | Demminger 2020 (104) | |
| SARS-CoV-1/2 | AAV2 | Mouse | IM | RBD/antigen | Du 2006 (63) |
| AAV2 | Mouse | IN | RBD/antigen | Du 2008 (105) | |
| AAVrh32.33 | IM | Spike/antigen | Vandenberghe and Freeman | ||
| Undisclosed | IN | bNAb | Wilson | ||
| Malaria | AAV1, AAV3 | Mouse | IM | MSP4/5/antigen | Logan 2007 (106) |
| AAV8 | Mouse | IM | mAb | Deal 2014 (107) | |
| AdHu5/AAV1 | Mouse | IM | PfCSP/Pfs25/antigen | Yusuf 2019a (108), 2019b (109) | |
| AAV8 | Mouse | IV | miR-155 | Hentzschel 2014 (110) | |
| HCV | AAV8 | Mouse | IV | NS5B/antigen | Mekonnen 2020 (111) |
| AAVrh32.33 | Mouse | IM | NS3/4/antigen | Zhu 2015 (112) | |
| AAV8, AAVrh32.33 | Mouse | IM | E2/antigen | Zhu 2019 (113) | |
| HPV/Cervical cancer | AAV1 | Mouse | IM | E7/antigen | Zhou 2010 (114) |
| AAV5, AAV9 | Rh.M. | IN | L1/antigen | Nieto 2012 (115) | |
| Ebola | AAV9 | Mouse | IM, IN | mAb | Limberis 2016 (116) |
| AAV9 | Mouse | IV, IM, IN | mAb | Robert 2017 (117) | |
| AAV6.2FF | Mouse | IM | mAb | van Lieshout 2018 (118) | |
| Dengue | AAV1 | Rh.M. | IM | mAb | Magnani 2017 (119) |
| AAVrh32.33, AAV8 | Mouse | IM | 79E/antigen | Li 2012 (120) | |
| AAV6, AAV9 | Mouse | SC, IM | EDIII/antigen | Slon-Campos 2020 (121) | |
| Prion | AAV2 | Mouse | IC | mAb-derived scFv | Wuertzer 2008 (82) |
| AAV2 | Mouse | IC | mAb-derived scFv | Zuber 2008 (122) | |
| AAV9 | Mouse | IC | mAb-derived scFv | Moda 2012 (123) | |
| Rabies | Mouse | IM | G/antigen | Liu 2020 (124) | |
| Anthrax | Ad5/AAVrh.10 | Mouse | IV/Intrapleural | mAb | De 2008 (30) |
| RSV | Ad5/AAVrh.10 | Mouse | IV/Intrapleural | mAb | Skaricic 2008 (28) |
IM, intramuscular; IN, intranasal; IV, intravenous; SC, subcutaneous; IC, intracerebral; Rh.M., rhesus macaques.